Double-Stapled Peptide D26 Directly Kills HIV Particles and Shows Potential for Oral Delivery
A hydrocarbon double-stapled peptide called D26, based on HIV's own gp41 protein, can directly inactivate free HIV particles (not just block replication), resists enzymatic breakdown, has a long half-life, and remarkably shows detectable oral absorption.
Quick Facts
What This Study Found
The double-stapled peptide D26 efficiently inhibits HIV-1 infection and directly inactivates cell-free virions, with high protease resistance, extended in vivo half-life, enhanced sanctuary site penetration, and detectable oral bioavailability.
Key Numbers
Double-stapled peptide D26; based on gp41 LLP3 motif; inhibited HIV-1 infection and inactivated cell-free virions.
How They Did This
Designed and synthesized a hydrocarbon double-stapled helical peptide based on the HIV-1 gp41 LLP3 motif. Tested for HIV-1 inhibition, direct virion inactivation, proteolytic stability, pharmacokinetics (half-life), tissue distribution (sanctuary site penetration), and oral absorption compared to linear/non-stapled version.
Why This Research Matters
HIV can hide in sanctuary sites (brain, testes, gut tissue) where current drugs barely reach, contributing to the inability to cure the infection. A long-acting peptide that penetrates these sites, directly kills free virus, AND can potentially be taken orally would be a game-changer for HIV treatment — addressing multiple unmet needs simultaneously.
The Bigger Picture
Peptide drugs have historically been limited by rapid breakdown in the body and inability to be taken orally. Double-stapling technology addresses both problems at once by locking the peptide into a protease-resistant helix. D26 demonstrates that stapled peptides can achieve what was once considered nearly impossible — oral bioavailability for a peptide therapeutic. Beyond HIV, this approach could revolutionize peptide drug delivery across many disease areas.
What This Study Doesn't Tell Us
Preclinical study — D26 has not been tested in humans. Oral bioavailability is described as 'detectable' not 'high' — it may not be sufficient for therapeutic dosing orally. Manufacturing double-stapled peptides at clinical scale is challenging and expensive. HIV resistance to D26 has not been assessed. Long-term safety of a gp41-derived peptide is unknown.
Questions This Raises
- ?Is D26's oral bioavailability high enough for therapeutic dosing, or will injectable formulations still be needed?
- ?Can HIV develop resistance to D26's virus-inactivation mechanism, given that it targets the virus's own structural protein?
- ?Could the double-stapling approach be applied to other antiviral peptides targeting different viruses?
Trust & Context
- Key Stat:
- Detectable oral absorption exceptionally rare for a peptide drug — D26's double-staple design provides protease resistance enabling it to survive the digestive tract, plus extended half-life and HIV sanctuary site penetration
- Evidence Grade:
- Preliminary — preclinical proof-of-concept with promising pharmacokinetic properties demonstrated in laboratory and animal studies, but no human clinical data yet.
- Study Age:
- Published in 2024 in Journal of Medicinal Chemistry, a top-tier journal for drug design and medicinal chemistry research.
- Original Title:
- Discovery of a Double-Stapled Short Peptide as a Long-Acting HIV-1 Inactivator with Potential for Oral Bioavailability.
- Published In:
- Journal of medicinal chemistry, 67(12), 9991-10004 (2024)
- Authors:
- Wang, Chao(3), Zhang, Wenpeng, Xu, Ling(2), Tu, Jiahuang, Su, Shan, Li, Qing, Zhang, Tao, Zheng, Longbo, Wang, Huan, Zhuang, Xiaomei, Tang, Xuan, Yuan, Yu, Meng, Guangpeng, Lu, Lu, Xiao, Junhai, Wang, Qian, Jiang, Shibo
- Database ID:
- RPEP-09469
Evidence Hierarchy
Frequently Asked Questions
What does 'double-stapled' mean for a peptide?
Peptides are normally flexible chains that enzymes in the body quickly chop up. 'Stapling' adds a chemical bridge (hydrocarbon chain) across the peptide that locks it into a rigid helix shape, like adding a brace to a floppy structure. A double staple adds two such bridges, making the peptide even more resistant to being broken down. This is why D26 survives in the body much longer than normal peptides and can even withstand the harsh environment of the digestive system.
Why is it important that D26 kills free virus particles?
Current HIV drugs only block the virus from replicating once it's already inside a cell — they don't touch free-floating virus particles in the blood. This means even on treatment, infectious virus particles continue circulating. D26 is a 'virus inactivator' that attacks and destroys free HIV particles before they can infect new cells — adding a completely new dimension to treatment that complements existing drugs.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09469APA
Wang, Chao; Zhang, Wenpeng; Xu, Ling; Tu, Jiahuang; Su, Shan; Li, Qing; Zhang, Tao; Zheng, Longbo; Wang, Huan; Zhuang, Xiaomei; Tang, Xuan; Yuan, Yu; Meng, Guangpeng; Lu, Lu; Xiao, Junhai; Wang, Qian; Jiang, Shibo. (2024). Discovery of a Double-Stapled Short Peptide as a Long-Acting HIV-1 Inactivator with Potential for Oral Bioavailability.. Journal of medicinal chemistry, 67(12), 9991-10004. https://doi.org/10.1021/acs.jmedchem.4c00150
MLA
Wang, Chao, et al. "Discovery of a Double-Stapled Short Peptide as a Long-Acting HIV-1 Inactivator with Potential for Oral Bioavailability.." Journal of medicinal chemistry, 2024. https://doi.org/10.1021/acs.jmedchem.4c00150
RethinkPeptides
RethinkPeptides Research Database. "Discovery of a Double-Stapled Short Peptide as a Long-Acting..." RPEP-09469. Retrieved from https://rethinkpeptides.com/research/wang-2024-discovery-of-a-doublestapled
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.